Aes-103

DRUG3 trials

Sponsors

Baxalta now part of Shire, Colorado State University

Conditions

HypoxiaSickle Cell Disease

Phase 1

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

CompletedNCT01597401

Baxalta now part of ShireSickle Cell Disease

Start: 2012-05-12End: 2013-06-07Updated: 2021-05-05

Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance

CompletedNCT01871142

Colorado State UniversityHypoxia

Start: 2013-03-31End: 2014-06-30Updated: 2014-10-24

Phase 2

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

TerminatedNCT01987908

Baxalta now part of ShireSickle Cell Disease

Start: 2013-12-03End: 2015-03-16Updated: 2021-05-25